Literature DB >> 17021484

Remifentanil: an update.

Frédérique S Servin1.   

Abstract

PURPOSE OF REVIEW: Remifentanil has now reached maturity, as reflected by the increasing number of clinical papers relating to its use. Its position among anaesthetic drugs is now better understood, and this review will attempt to place it in the context of current clinical practice. RECENT FINDINGS AND
SUMMARY: Propofol reduces the initial distribution of remifentanil, leading to higher concentrations during induction. Propofol and remifentanil administered together at sedative doses display a major synergistic interaction on the respiratory drive. Remifentanil accelerates the penetration of sevoflurane to its site of effect. The risk of intraoperative awareness seems to be low when remifentanil is associated to very low concentrations of hypnotic drugs, but this field warrants further investigation. Acute tolerance to opioids and its prevention remain controversial.
SUMMARY: Remifentanil is the opioid of choice for tracheal intubation without muscle relaxants. It provides an alternative to regional anaesthesia in labour pain control. Target-controlled infusion may further improve the administration of remifentanil.

Entities:  

Year:  2003        PMID: 17021484     DOI: 10.1097/01.aco.0000084479.59960.3f

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  3 in total

1.  Continuous infusion of two doses of remifentanil immediately after laparoscopic-assisted vaginal hysterectomy.

Authors:  Jae Jun Lee; Sung Mi Hwang; Jun Sung Lee; Sung Jun Hong; Soo Kyung Lee; So Young Lim
Journal:  Korean J Anesthesiol       Date:  2010-06-23

2.  Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial [ISRCTN50308308].

Authors:  Andreas Karabinis; Kostas Mandragos; Spiros Stergiopoulos; Apostolos Komnos; Jens Soukup; Ben Speelberg; Andrew J T Kirkham
Journal:  Crit Care       Date:  2004-06-28       Impact factor: 9.097

Review 3.  Opioid Drugs in Patients With Liver Disease: A Systematic Review.

Authors:  Hassan Soleimanpour; Saeid Safari; Kavous Shahsavari Nia; Sarvin Sanaie; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-03-06       Impact factor: 0.660

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.